fracture, which might require medical intervention. [4] [5] [6] Furthermore, a recent large cohort study reported that 24.3% of 107 patients with PLO had one or more subsequent fractures during a median follow-up of 6 years. 9 The risk was positively correlated with the number of fractures at the time of diagnosis, suggesting that severe PLO carries a substantial risk of fracture, which must be taken into consideration. 9 Given concerns regarding foetal toxicity of bisphosphonates in women of reproductive age, therapy with teriparatide (TPTD), a recombinant human parathyroid hormone 1-34, has been considered a potential pharmacological intervention for severe, refractory cases of PLO. 8, [10] [11] [12] [13] In prior studies, TPTD administration was associated with increases in spine and hip bone mineral density (BMD) in premenopausal women with idiopathic osteoporosis or glucocorticoid-induced osteoporosis, without serious adverse events. 14 TPTD therapy was also associated with increased BMD in patients with PLO in anecdotal case
reports, but the magnitude of this increase varied substantially (from 14% to 36%) within the heterogeneous follow-up period. 11, 12, 15, 16 Studies on longitudinal changes in BMD and bone markers after TPTD treatment in patients with PLO have been scarce, partly because of the rarity of this condition. Furthermore, most of the reported case series did not include controls without TPTD treatment.
In this study, we investigated the changes in BMD, particularly at the lumbar spine, and bone markers in patients with PLO who underwent or did not undergo TPTD treatment during a 12-month follow-up.
Furthermore, we aimed to identify independent factors associated with greater increases in lumbar spine BMD (LSBMD) in patients with PLO.
| MATERIAL S AND ME THODS

| Study subjects
Data of premenopausal women who were diagnosed with PLO accompanied by vertebral fractures at the Severance Hospital, Yonsei
University College of Medicine (Seoul, Korea), between October 2007
and November 2015 were retrieved from the electronic medical records system of this institution. PLO was defined as occurrence of fragility fracture(s) in the third trimester of pregnancy or postpartum without any evidences of secondary osteoporosis related to malignancy, oestrogen deficiency, hyperparathyroidism, diabetes mellitus, uncontrolled endocrinopathies, anorexia nervosa, malabsorption syndromes, exposure to drugs that can disturb bone metabolism or newly diagnosed osteogenesis imperfecta. All patients were examined and treated by an experienced endocrinologist (YR) according to a standard protocol with a regular follow-up interval of 3 months. Out of 51 patients diagnosed with PLO, 46 patients who agreed to undergo the treatment received a daily dose of 20 μg of TPTD subcutaneously along with 100-500 mg of elemental calcium and 1000 IU of cholecalciferol supplements ( Figure 1 ). Five subjects that refused to undergo the TPTD treatment received calcium and vitamin D supplementation only and were analysed separately as controls. After excluding those who had had more than 6 months of bisphosphonate exposure before TPTD therapy initiation (n = 5), discontinued TPTD because of subsequent pregnancy (n = 2), were lost to follow-up before the end of the 12-month study period (n = 3), did not undergo a follow-up BMD measurement (n = 5) or underwent BMD measurements by quantitative computed tomography (n = 4), 27 TPTD-treated subjects were analysed. Therefore, 32 subjects (27 patients treated with TPTD and 5 patients treated with vitamin D and calcium supplements only) remained in the final analysis. Demographics and information regarding pregnancy, prior fractures, medications and family history were extracted from medical charts. This study was approved by the institutional review board of Severance Hospital (IRB no. 4-2017-0531).
| Bone density and vertebral fracture assessment
Lumbar spine (LSBMD), femur neck (FNBMD) and total hip (THBMD) areal BMD were measured by dual-energy X-ray absorptiometry 
| Laboratory assessment
Overnight fasting blood samples were drawn at the first or second visit before the initiation of any pharmacological intervention to as- Cohen's f 2 were set to 0.05, 3 and 0.35 (empirical value for a large effect size), respectively, the power was 0.89 for the study population (n = 32). 18 A two-sided P value of < .05 was considered to indicate a statistically significant difference. All statistical analyses were performed with STATA 14.0 (Stata Corp, College Station, TX, USA).
| RE SULTS
| Baseline characteristics of study subjects
The mean age and body mass index (BMI) of the study subjects were 31.3 ± 2.6 years and 20.3 ± 2.4 kg/m 2 , respectively (Table 1) 
| Changes in BMD
At 12 months, LSBMD improved in both the TPTD (by 16.2 ± 8.1%, P < .001) and control (by 3.5 ± 2.7%, P = .045) groups (Figure 2A) , with a greater increase in the TPTD group (P = .002). After adjustment for baseline LSBMD and age, the difference in the changes in LSBMD between the TPTD and control groups remained significant ( Figure 2B ; adjusted LSBMD change 15.5 ± 6.6% in the TPTD group vs 7.5 ± 7.1% in the control group, P = .020). There were also significant increases in the femoral neck (5.4 ± 7.9%, P = .002) and total hip (5.2 ± 6.2%, P < .001) BMD in the TPTD-treated subjects.
Adverse events such as new fragility fractures, hypercalcaemia or hyperuricaemia were not detected during the follow-up period.
| Changes in bone turnover markers
At baseline, there were no significant differences in serum OCN and CTX levels between the TPTD-treated subjects and controls ( Table 1 ).
The mean serum CTX levels in both groups were at the upper limit of the normal range for premenopausal women (<573.0 ng/L). In the subjects treated with TPTD, serum OCN level peaked at 3 months (+86.6%) and then decreased towards the baseline value at 6, 9 and 12 months ( Figure 3A ; P < .05 compared to baseline value after adjustment for age and baseline LSBMD). Serum CTX level increased gradually to a lesser extent than serum OCN level, peaking at 6 months (+46.4%), and decreased to the baseline value afterwards ( Figure 3B ). In the controls, serum OCN level tended to increase at 6 months (+27.5%), but the changes in OCN and CTX levels vs baseline did not reach the level of statistical significance during the follow-up ( Figure 3A, B) . The observed differences in the pattern of changes in serum OCN level between the TPTD-treated subjects and the controls were significant at 3 months (P for interaction = .018).
| Factors associated with greater increases in LSBMD
In the univariate analysis, younger age, lower baseline LSBMD and TPTD treatment were associated with a greater increase in LSBMD 
| D ISCUSS I ON
In patients with PLO who experienced multiple vertebral fractures, LSBMD improved at 12 months of follow-up both in subjects who TA B L E 1 Baseline characteristics of subjects with pregnancy-and lactation-associated osteoporosis in serum OCN and CTX levels were observed in TPTD-treated subjects.
Treatment with TPTD and younger age were associated with greater improvements in BMD of the lumbar spine, irrespective of baseline BMD.
In previous case reports, TPTD therapy was associated with a 14%-36% increase in LSBMD in patients with PLO after 12-18 months of treatment. 11, 12, 15, 16 In this study, there was an increase in LSBMD, with a wide range of responses (from +4.5% to +34.3%), in patients with PLO and multiple vertebral fractures after 12 months of TPTD treatment, which is consistent with previous findings. The BMD gain achieved by the TPTD treatment in patients with PLO (15.5 ± 6.6% at 12 months) was greater than that previously reported in premenopausal women with idiopathic osteoporosis (10.8 ± 8.3% at 24 months). 14 It is possible that 2 factors, the spontaneous bone recovery after weaning and the anabolic effect of TPTD, cumulatively contributed to the increase in BMD in patients with PLO in this study. The extent of spontaneous recovery of BMD varied significantly (within a range of 6%-70%) in the anecdotal reports with different follow-up periods and supplement types. 3 In an individual case, LSBMD increased by 8% and 21.4% at 16 months and 5 years of follow-up, respectively, with active vitamin D supplementation. 19 In our study, the LSBMD increase in the control group, with adjustments for age and baseline LSBMD, was estimated to be 7.5% at 12 months of follow-up, which is within the range of BMD increase after weaning in the anecdotal cases where patients were treated with calcium and vitamin D supplements. 2, 20, 21 Although the spontaneous gain in LSBMD in the controls treated with calcium and vitamin D supplements only was substantial, we found that treatment with TPTD was associated with an additional increase in LSBMD in patients with PLO, irrespective of age and baseline LSBMD. However, this result should be interpreted in the light of substantial individual heterogeneity in spontaneous changes in bone metabolism after weaning. 3 Although levels of bone turnover markers were reported to increase spontaneously after weaning and after fracture, marked increases in serum OCN and CTX levels were observed in the TPTD group compared with the control group in our study. 3 The pattern of changes in serum bone markers levels during the TPTD treatment resembles that in previous studies of TPTD effects in women with pre-or postmenopausal osteoporosis, indicating the existence of an anabolic window during the first 6 months in which bone formation exceeds resorption. [22] [23] [24] [25] Our data also support previous findings in premenopausal women with idiopathic osteoporosis or oestrogen deficiency-related bone loss, in whom early changes in serum OCN level during TPTD treatment were correlated with response to TPTD. 14, 24 However, the association of baseline OCN and CTX levels F I G U R E 2 (A) Unadjusted per cent change in BMD at the lumbar spine, femoral neck and total hip at 12 mo and (B) per cent change in BMD adjusted for baseline BMD at each site and for age using analysis of covariance. Abbreviations: BMD, bone mineral density; TPTD, teriparatide. *P < .05 vs baseline; †P < .05 between TPTD-treated subjects and controls F I G U R E 3 Changes in the levels of (A) serum osteocalcin (OCN) and (B) serum C-terminal cross-linked telopeptide of type I collagen (CTX) in teriparatide (TPTD)-treated subjects and in the control group. Abbreviations: CTX, C-terminal cross-linked telopeptide of type I collagen; OCN, osteocalcin; TPTD, teriparatide. *indicates a significant change from baseline (P < .05 for all) after adjustment for age and baseline lumbar spine bone mineral density in the linear mixed model. The mechanisms underlying the variability in degree of bone mass recovery in patients with PLO observed in this study remain unclear. Given the high prevalence of low dietary calcium intake in Korea and wide individual variations in calcium absorption efficiency in healthy women, insufficient calcium intake at baseline might affect the recovery of bone density after weaning despite the continuous calcium and vitamin D supplementation during the follow-up in our subjects. 28, 29 Although relatively young age and low baseline BMD, along with TPTD treatment, was initially associated with greater increases in BMD, only young age remained an independent factor in the multivariate model. An age-related decrease in osteoblast response to PTH or differences in IGF-1 level can be postulated as a relevant mechanism of the association between younger age and greater BMD increases in patients with PLO, but these speculations need verification. 14, 30, 31 Although we excluded cases with newly diagnosed osteogenesis imperfecta from the study, potential genetic underlying causes, such as a heterozygous LRP5 mutation, in study subjects cannot be ruled out. 32 Our study is limited by its retrospective observational design.
Although a relatively small sample size and a nonrandomized control design were inevitable owing to the rarity of the disease, the effect size of the primary outcome in the regression model was larger than the expected value of 0.35, which led to an actual power of 0.93 at an alpha level of 0.05. The controls used in this study might not be optimal for comparing the effects of TPTD in patients with PLO. A possibility of unmeasured bias cannot be excluded because of the observational study design and a small sample size despite the statistical adjustment. Although the proportion of excluded TPTD-treated patients was substantial (n = 19/47) owing to the observational nature of this study, the excluded subjects did not differ significantly in baseline characteristics from the TPTD-treated subjects that were included in the analysis (Table S1 ). Furthermore, the association of . 33 The BMD values before the development of PLO were not available because before pregnancy most subjects were healthy premenopausal women. Thus, a possibility of a contribution of low peak bone mass to the occurrence of fragility fractures in our subjects cannot be ruled out.
To summarize, in patients with PLO, BMD at the lumbar spine improved at 12 months in both the TPTD-treated and control groups.
Treatment with TPTD was associated with a marked increase in serum bone markers levels during the follow-up period. TPTD treatment and younger age were associated with a greater increase in LSMBD, irrespective of baseline LSBMD.
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